Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Master Framework For Relapse or Refractory Acute Myeloid Leukemia- IMPACT STREAM - A Prospective Observational Study of Treatment Outcomes
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
4,000 participants
Jun 28, 2024
OBSERVATIONAL
Conditions
Summary
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Eligibility
Inclusion Criteria3
- Patients with AML diagnosis according to WHO2022 or ICC2022
- Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria
- Participant or his/her legal representative is willing and able to give informed consent for participation in the study
Exclusion Criteria1
- Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.
Interventions
All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06459024